Skip to Content
You are currently on the new version of our website. Access the old version .

51 Results Found

  • Article
  • Open Access
12 Citations
3,959 Views
12 Pages

Impact of 18F-FDG PET/CT on Clinical Management of Suspected Radio-Iodine Refractory Differentiated Thyroid Cancer (RAI-R-DTC)

  • Elisa Lodi Rizzini,
  • Andrea Repaci,
  • Elena Tabacchi,
  • Lucia Zanoni and ,
  • Valentina Vicennati,
  • Ottavio Cavicchi,
  • Uberto Pagotto,
  • Alessio Giuseppe Morganti,
  • Stefano Fanti and
  • Fabio Monari
  • + 5 authors+ 0 author

Background: As reported in the literature, [18F]-fluorodeoxyglucose positron emission tomography/computed tomography ([18F]-FDG PET/CT) provides useful qualitative and semi-quantitative data for the prognosis of advanced differentiated thyroid cancer...

(This article belongs to the Special Issue Image-Based Diagnostics and Radiometabolic Therapy of Differentiated Thyroid Cancer)
  • Review
  • Open Access
17 Citations
5,268 Views
15 Pages

Molecular Theranostics in Radioiodine-Refractory Differentiated Thyroid Cancer

  • Petra Petranović Ovčariček,
  • Alfredo Campenni,
  • Bart de Keizer,
  • Desiree Deandreis and ,
  • Michael C. Kreissl,
  • Alexis Vrachimis,
  • Murat Tuncel and
  • Luca Giovanella
  • + 3 authors+ 0 author

27 August 2023

Differentiated thyroid cancer (DTC) is the most common subtype of thyroid cancer and has an excellent overall prognosis. However, metastatic DTC in certain cases may have a poor prognosis as it becomes radioiodine-refractory. Molecular imaging is ess...

(This article belongs to the Special Issue Thyroid Cancer: New Advances from Diagnosis to Therapy)
  • Protocol
  • Open Access
11 Citations
4,187 Views
14 Pages

Reinducing Radioiodine-Sensitivity in Radioiodine-Refractory Thyroid Cancer Using Lenvatinib (RESET): Study Protocol for a Single-Center, Open Label Phase II Trial

  • Maaike Dotinga,
  • Dennis Vriens,
  • Floris H. P. van Velden,
  • Mette K. Stam and ,
  • Jan W. T. Heemskerk,
  • Petra Dibbets-Schneider,
  • Martin Pool,
  • Daphne D. D. Rietbergen,
  • Lioe-Fee de Geus-Oei and
  • Ellen Kapiteijn
  • + 5 authors+ 0 author

14 December 2022

Background: Management of patients with radioiodine (RAI)-refractory differentiated thyroid cancer (DTC) is a challenge as I-131 therapy is deemed ineffective while standard-of-care systemic therapy with tyrosine kinase inhibitor (TKI) lenvatinib is...

(This article belongs to the Special Issue Recent Advances in Thyroid Carcinoma)
  • Review
  • Open Access
36 Citations
14,801 Views
15 Pages

Current Advances in Radioactive Iodine-Refractory Differentiated Thyroid Cancer

  • Fabio Volpe,
  • Carmela Nappi,
  • Emilia Zampella,
  • Erica Di Donna and ,
  • Simone Maurea,
  • Alberto Cuocolo and
  • Michele Klain
  • + 2 authors+ 0 author

3 July 2024

Background: Differentiated thyroid cancer (DTC) patients have an outstanding overall long-term survival rate, and certain subsets of DTC patients have a very high likelihood of disease recurrence. Radioactive iodine (RAI) therapy is a cornerstone in...

(This article belongs to the Topic Recent Advances in Anticancer Strategies)
  • Review
  • Open Access
6 Citations
4,668 Views
15 Pages

27 January 2025

Differentiated thyroid cancer (DTC), which includes papillary and follicular thyroid cancers, differs significantly in pathology compared to other thyroid malignancies such as medullary thyroid cancer (MTC), anaplastic thyroid cancer (ATC), and Hurth...

(This article belongs to the Special Issue Head and Neck Cancer: Advanced PET/CT and MRI Imaging with a Focus on Current and Emerging Molecular Theranostics)
  • Review
  • Open Access
3 Citations
2,705 Views
22 Pages

Molecular Mechanisms of Radioiodine Refractoriness in Differentiated Thyroid Cancer: Focus on Sodium/Iodide Symporter Dysregulation

  • Vladimir D. Rokashkov,
  • Liudmila V. Spirina,
  • Natalya V. Tarasenko and
  • Svetlana Yu. Chizhevskaya

The sodium/iodide symporter (NIS/SLC5A5) is a major determinant of radioiodine therapy efficacy in differentiated thyroid cancer (DTC). This narrative review examines the molecular mechanisms underlying NIS dysregulation and radioiodine refractorines...

(This article belongs to the Special Issue Molecular Markers of Tumor Response and Toxicity of Antitumor Therapy)
  • Review
  • Open Access
15 Citations
5,415 Views
16 Pages

Redifferentiation Therapies in Thyroid Oncology: Molecular and Clinical Aspects

  • Petra Petranović Ovčariček,
  • Murat Tuncel,
  • Atena Aghaee,
  • Alfredo Campennì and
  • Luca Giovanella

21 November 2024

Since the 1940s, 131-I radioiodine therapy (RIT) has been the primary treatment for metastatic differentiated thyroid cancer (DTC). Approximately half of these patients respond favorably to RIT, achieving partial or complete remission or maintaining...

(This article belongs to the Special Issue Thyroid Disease: Updates from Diagnosis to Treatment)
  • Review
  • Open Access
2 Citations
1,531 Views
26 Pages

31 March 2026

Differentiated thyroid cancer (DTC), including papillary and follicular subtypes, is generally associated with favorable prognosis; however, a subset of patients develops recurrent, metastatic, or radioiodine-refractory diseases with limited therapeu...

(This article belongs to the Special Issue Emerging Mechanisms and Therapeutic Strategies in Head and Neck Cancer)
  • Review
  • Open Access
178 Citations
27,438 Views
17 Pages

Differentiated Thyroid Cancer—Treatment: State of the Art

  • Benedikt Schmidbauer,
  • Karin Menhart,
  • Dirk Hellwig and
  • Jirka Grosse

Differentiated thyroid cancer (DTC) is a rare malignant disease, although its incidence has increased over the last few decades. It derives from follicular thyroid cells. Generally speaking, the prognosis is excellent. If treatment according to the c...

(This article belongs to the Special Issue Current Knowledge in Thyroid Cancer—From Bench to Bedside)
  • Review
  • Open Access
87 Citations
9,928 Views
33 Pages

Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice

  • Elena Tirrò,
  • Federica Martorana,
  • Chiara Romano,
  • Silvia Rita Vitale and ,
  • Gianmarco Motta,
  • Sandra Di Gregorio,
  • Michele Massimino,
  • Maria Stella Pennisi,
  • Stefania Stella and
  • Paolo Vigneri
  • + 9 authors+ 4 authors

13 September 2019

Thyroid cancer comprises different clinical and histological entities. Whereas differentiated (DTCs) malignancies are sensitive to radioiodine therapy, anaplastic (ATCs) and medullary (MTCs) tumors do not uptake radioactive iodine and display aggress...

(This article belongs to the Special Issue Thyroid Cancer: Genetics and Targeted Therapies)
  • Article
  • Open Access
15 Citations
4,696 Views
28 Pages

30 October 2021

The functional expression of the sodium–iodide symporter (NIS) at the membrane of differentiated thyroid cancer (DTC) cells is the cornerstone for the use of radioiodine (RAI) therapy in these malignancies. However, NIS gene expression is frequently...

(This article belongs to the Special Issue Role of Small GTPase Signaling in Tumorigenesis)
  • Article
  • Open Access
756 Views
20 Pages

BRAF V600E/TERT Promoter Co-Mutation Is Associated with Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Translational Molecular Biomarker Study

  • Madina A. Mussulmanova,
  • Laura A. Pak,
  • Aidana M. Rakhmankulova,
  • Arailym Baurzhan and ,
  • Lyudmila M. Pivina,
  • Diana A. Pak,
  • Zhandos K. Burkitbayev,
  • Andrey Yu. Orekhov,
  • Azhar S. Baktiyar and
  • Masahiro Nakashima
  • + 6 authors+ 1 author

Background/Objectives: Radioiodine-refractory differentiated thyroid carcinoma (RAIR-DTC) is associated with limited treatment options and a less favorable clinical course. Combining molecular alterations with clinicopathological characteristics may...

(This article belongs to the Section Cancer Biology and Oncology)
  • Review
  • Open Access
11 Citations
5,109 Views
12 Pages

Positron Emission Tomography Radiopharmaceuticals in Differentiated Thyroid Cancer

  • Chaninart Sakulpisuti,
  • Putthiporn Charoenphun and
  • Wichana Chamroonrat

3 August 2022

Differentiated thyroid cancer (DTC), arising from thyroid follicular epithelial cells, is the most common type of thyroid cancer. Despite the well-known utilization of radioiodine treatment in DTC, i.e., iodine-131, radioiodine imaging in DTC is typi...

(This article belongs to the Special Issue Radiopharmaceuticals for PET Imaging - Issue B)
  • Review
  • Open Access
2 Citations
1,062 Views
17 Pages

The Role of 123I in the Management of Differentiated Thyroid Cancer: A Comprehensive Narrative Review

  • Pietro Bellini,
  • Francesco Dondi,
  • Michela Cossandi,
  • Gianluca Viganò and ,
  • Carlo Cappelli,
  • Elisa Gatta,
  • Davide Lombardi,
  • Riccardo Morandi,
  • Claudio Casella and
  • Francesco Bertagna
  • + 10 authors+ 5 authors

2 February 2026

Differentiated thyroid carcinoma (DTC) is the most common malignant endocrine tumor, with a generally favorable prognosis. Imaging, including iodine radioactive isotope scintigraphy (IRIS), is crucial for diagnosis and follow-up. While 131I has long...

(This article belongs to the Section Cancer and Cancer-Related Research)
  • Review
  • Open Access
33 Citations
10,414 Views
27 Pages

State of the Art in the Current Management and Future Directions of Targeted Therapy for Differentiated Thyroid Cancer

  • Horatiu Silaghi,
  • Vera Lozovanu,
  • Carmen Emanuela Georgescu,
  • Cristina Pop and ,
  • Bogdana Adriana Nasui,
  • Adriana Florinela Cătoi and
  • Cristina Alina Silaghi
  • + 2 authors+ 0 author

Two-thirds of differentiated thyroid cancer (DTC) patients with distant metastases would be classified as radioactive iodine-refractory (RAIR-DTC), evolving into a poor outcome. Recent advances underlying DTC molecular mechanisms have shifted the the...

(This article belongs to the Section Molecular Immunology)
  • Review
  • Open Access
7 Citations
4,968 Views
23 Pages

Kinase-Inhibitors in Iodine-Refractory Differentiated Thyroid Cancer—Focus on Occurrence, Mechanisms, and Management of Treatment-Related Hypertension

  • Anne Christine Kaae,
  • Michael C. Kreissl,
  • Marcus Krüger,
  • Manfred Infanger and ,
  • Daniela Grimm and
  • Markus Wehland
  • + 1 author+ 0 author

12 November 2021

Differentiated thyroid cancer (DTC) usually has a good prognosis when treated conventionally with thyroidectomy, radioactive iodine (RAI) and thyroid-stimulating hormone suppression, but some tumors develop a resistance to RAI therapy, requiring alte...

(This article belongs to the Special Issue Recent Advances in Thyroid Cancer Research)
  • Review
  • Open Access
50 Citations
6,718 Views
22 Pages

Molecular Imaging and Theragnostics of Thyroid Cancers

  • Luca Giovanella,
  • Desiree’ Deandreis,
  • Alexis Vrachimis,
  • Alfredo Campenni and
  • Petra Petranovic Ovcaricek

1 March 2022

Molecular imaging plays an important role in the evaluation and management of different thyroid cancer histotypes. The existing risk stratification models can be refined, by incorporation of tumor-specific molecular markers that have theranostic powe...

(This article belongs to the Special Issue Recent Developments of Nuclear Medicine in Cancer Diagnosis and Theranostics)
  • Review
  • Open Access
2 Citations
1,815 Views
30 Pages

Theranostic Approaches to Radioiodine-Refractory Differentiated Thyroid Cancer: A Narrative Review

  • Petra Petranović Ovčariček,
  • Murat Tuncel,
  • Martin W. Huellner,
  • Alfredo Campennì and
  • Luca Giovanella

14 June 2026

Background: Radioiodine (Na[131I]I) therapy is the cornerstone of systemic treatment for differentiated thyroid cancer (DTC), exploiting sodium–iodide symporter (NIS) expression for durable control. Up to 30–40% of advanced cases develop...

(This article belongs to the Special Issue Thyroid Cancer: Diagnosis, Prognosis and Treatment—3rd Edition)
  • Article
  • Open Access
10 Citations
4,100 Views
19 Pages

Efficacy and Biomarker Analysis of Adavosertib in Differentiated Thyroid Cancer

  • Yu-Ling Lu,
  • Ming-Hsien Wu,
  • Yi-Yin Lee,
  • Ting-Chao Chou and ,
  • Richard J. Wong and
  • Shu-Fu Lin
  • + 1 author+ 0 author

12 July 2021

Differentiated thyroid cancer (DTC) patients are usually known for their excellent prognoses. However, some patients with DTC develop refractory disease and require novel therapies with different therapeutic mechanisms. Targeting Wee1 with adavoserti...

  • Review
  • Open Access
8 Citations
4,919 Views
22 Pages

Pathogenesis and Management Strategies in Radioiodine-Refractory Differentiated Thyroid Cancer: From Molecular Mechanisms Toward Therapeutic Approaches: A Comprehensive Review

  • Iulia-Alexandra Voinea,
  • Eugenia Petrova,
  • Nicoleta Dumitru,
  • Andra Cocoloș and ,
  • Dumitru Ioachim,
  • Andrei Liviu Goldstein and
  • Adina Mariana Ghemigian
  • + 2 authors+ 0 author

26 November 2024

Thyroid cancer (TC) remains the most common cancer in endocrinology. Differentiated thyroid cancer (DTC), the most common type of TC, generally has a favorable outlook with conventional treatment, which typically includes surgery along with radioiodi...

(This article belongs to the Special Issue From Endocrine Tumors Requiring Surgery to Endocrine Issues of Different Surgical Conditions)
  • Review
  • Open Access
30 Citations
5,694 Views
15 Pages

Redox Homeostasis in Thyroid Cancer: Implications in Na+/I− Symporter (NIS) Regulation

  • Juliana Cazarin,
  • Corinne Dupuy and
  • Denise Pires de Carvalho

Radioiodine therapy (RAI) is a standard and effective therapeutic approach for differentiated thyroid cancers (DTCs) based on the unique capacity for iodide uptake and accumulation of the thyroid gland through the Na+/I− symporter (NIS). Howeve...

(This article belongs to the Section Molecular Biology)
  • Review
  • Open Access
10 Citations
3,692 Views
12 Pages

Early Predictive Response to Multi-Tyrosine Kinase Inhibitors in Advanced Refractory Radioactive-Iodine Differentiated Thyroid Cancer: A New Challenge for [18F]FDG PET/CT

  • Cristina Ferrari,
  • Giulia Santo,
  • Rossella Ruta,
  • Valentina Lavelli and ,
  • Dino Rubini,
  • Paolo Mammucci,
  • Angela Sardaro and
  • Giuseppe Rubini
  • + 3 authors+ 0 author

Differentiated thyroid cancer (DTC) represents the most common thyroid cancer histotype. Generally, it exhibits a good prognosis after conventional treatments; nevertheless, about 20% of patients can develop a local recurrence and/or distant metastas...

(This article belongs to the Special Issue Image-Based Diagnostics and Radiometabolic Therapy of Differentiated Thyroid Cancer)
  • Review
  • Open Access
93 Citations
12,371 Views
37 Pages

Novel Targeted Therapies for Metastatic Thyroid Cancer—A Comprehensive Review

  • Mohammad Al-Jundi,
  • Shilpa Thakur,
  • Sriram Gubbi and
  • Joanna Klubo-Gwiezdzinska

29 July 2020

The knowledge on thyroid cancer biology has grown over the past decade. Thus, diagnostic and therapeutic strategies to manage thyroid cancer are rapidly evolving. With new insights into tumor biology and cancer genetics, several novel therapies have...

(This article belongs to the Section Clinical Research in Cancer)
  • Review
  • Open Access
7 Citations
4,192 Views
22 Pages

Molecular Diagnostics and Personalized Therapeutics in Differentiated Thyroid Carcinoma: A Clinically Oriented Review

  • Andrés Coca-Pelaz,
  • Juan Pablo Rodrigo,
  • Mark Zafereo,
  • Iain Nixon and ,
  • Pia Pace-Asciak,
  • Gregory W. Randolph,
  • Carlos Suárez and
  • Alfio Ferlito
  • + 3 authors+ 0 author

30 September 2025

Differentiated thyroid carcinoma (DTC) is the most common endocrine malignancy and typically has a favorable prognosis. However, a subset of patients experience aggressive disease, recurrence, or treatment resistance, underscoring the need for more p...

(This article belongs to the Special Issue Advances in Molecular Pathology and Imaging for Precision Diagnosis and Treatment of Tumors)
  • Article
  • Open Access
557 Views
13 Pages

Real-World Outcomes of Lenvatinib in Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Multicentre Retrospective Study

  • Wing-Lok Chan,
  • Winnie Wing-Yan Tin,
  • Kenneth Chun-Wai Wong,
  • Carol Chi-Hei Kwok and ,
  • James C. H. Chow,
  • Tsz-Chim Liu,
  • Gavin Tin-Chun Cheung,
  • Wesley Yuen-Lum Choi,
  • Lok-Sze Joyce Au and
  • Dora Lai-Wan Kwong
  • + 10 authors+ 5 authors

6 September 2026

Background: Lenvatinib is an established first-line therapy for radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC); however, real-world data, particularly from Asian populations with long-term follow-up, remain limited. Methods:...

(This article belongs to the Special Issue Thyroid Cancer: Diagnosis, Prognosis and Treatment—3rd Edition)
  • Article
  • Open Access
11 Citations
3,381 Views
17 Pages

Needs, Preferences, and Values during Different Treatment Decisions of Patients with Differentiated Thyroid Cancer

  • Anna Koot,
  • Romana Netea-Maier,
  • Petronella Ottevanger,
  • Rosella Hermens and
  • Peep Stalmeier

20 July 2021

Background: The purpose of this study was to identify the needs, preferences, and values of patients with differentiated thyroid cancer (DTC) and the physicians treating patients with DTC regarding two different treatment decisions, namely: the exten...

(This article belongs to the Special Issue Present and Future of Personalised Medicine for Endocrine Cancers)
  • Article
  • Open Access
689 Views
17 Pages

The Correlation Between the Presence of BRAFV600E and TERT Promoter Mutation and the Response to Treatment with Iodine 131 in Differentiated Thyroid Cancer Patients

  • Roko Granić,
  • Ivan Blažeković,
  • Josipa Miš,
  • Ivan Šamija and ,
  • Tihana Regović Džombeta,
  • Gorana Mirošević,
  • Denis Bakunić,
  • Kristina Kralik,
  • Ana Fröbe and
  • Tomislav Jukić
  • + 6 authors+ 1 author

31 May 2026

Objectives: The response to radioiodine therapy (RAI) in differentiated thyroid cancer (DTC) patients is one of the most important factors that determines the treatment outcome and overall prognosis. The objective of this study is to determine the co...

(This article belongs to the Section Molecular Genetics and Genomics)
  • Article
  • Open Access
3 Citations
1,575 Views
31 Pages

Gadd45B Deficiency Drives Radio-Resistance in BRAFV600E-Mutated Differentiated Thyroid Cancer by Disrupting Iodine Metabolic Genes

  • Shan Jiang,
  • Zhiwen Hong,
  • Qianjiang Wu,
  • Rouhan A and ,
  • Zhaobo Wang,
  • Xue Guan,
  • Xinghua Wang,
  • Ari A. Kassardjian,
  • Yali Cui and
  • Tengchuang Ma
  • + 5 authors+ 0 author

30 September 2025

Background: Differentiated thyroid cancer (DTC) is commonly treated with radioactive iodine (RAI), but resistance to RAI remains a significant clinical challenge. The molecular mechanisms driving dedifferentiation and RAI refractoriness, particularly...

(This article belongs to the Section Cancer Therapy)
  • Review
  • Open Access
9 Citations
3,662 Views
16 Pages

Predictors of Response and Survival to Multikinase Inhibitors in Radioiodine Resistant Differentiated Thyroid Cancer

  • Tiziana Feola,
  • Alessia Cozzolino,
  • Roberta Centello,
  • Carla Pandozzi and ,
  • Maria Grazia Tarsitano and
  • Elisa Giannetta
  • + 1 author+ 0 author

18 July 2021

Sorafenib and lenvatinib are the only multikinase inhibitors (MKIs) approved for the treatment of radioactive iodine refractory differentiated thyroid cancer (RR-DTC). Although they have been demonstrated to improve progression free survival and over...

(This article belongs to the Special Issue Present and Future of Personalised Medicine for Endocrine Cancers)
  • Article
  • Open Access
28 Citations
3,969 Views
13 Pages

18F-FDG-PET/CT in Patients with Advanced, Radioiodine Refractory Thyroid Cancer Treated with Lenvatinib

  • Freba Ahmaddy,
  • Caroline Burgard,
  • Leonie Beyer,
  • Viktoria Florentine Koehler and ,
  • Peter Bartenstein,
  • Matthias P. Fabritius,
  • Thomas Geyer,
  • Vera Wenter,
  • Harun Ilhan and
  • Andrei Todica
  • + 6 authors+ 1 author

16 January 2021

Background: The tyrosine kinase inhibitor (TKI) Lenvatinib represents one of the most effective therapeutic options in patients with advanced radioiodine refractory differentiated thyroid carcinoma (DTC). We aimed to assess the role of 2-deoxy-2-[18F...

(This article belongs to the Special Issue Advances in the Diagnosis and Treatment of Thyroid Carcinoma)
  • Review
  • Open Access
21 Citations
5,935 Views
17 Pages

10 May 2021

Differentiated thyroid cancer is usually a slow-growing disease, even if the patients develop distant metastasis. For recurrent or metastatic disease, radioactive iodine therapy is a standard treatment. However, the disease gradually progresses in so...

(This article belongs to the Special Issue Advances in Thyroid Carcinoma)
  • Article
  • Open Access
6 Citations
3,594 Views
18 Pages

MAPK Inhibition Requires Active RAC1 Signaling to Effectively Improve Iodide Uptake by Thyroid Follicular Cells

  • Márcia Faria,
  • Rita Domingues,
  • Maria João Bugalho,
  • Paulo Matos and
  • Ana Luísa Silva

22 November 2021

The Sodium/Iodide Symporter (NIS) is responsible for the active transport of iodide into thyroid follicular cells. Differentiated thyroid carcinomas (DTCs) usually preserve the functional expression of NIS, allowing the use of radioactive iodine (RAI...

(This article belongs to the Special Issue Role of Small GTPase Signaling in Tumorigenesis)
  • Article
  • Open Access
1 Citations
3,318 Views
14 Pages

Radiofrequency Ablation for Locoregional Structural Incomplete Response in Differentiated Thyroid Cancer: Initial Experience in Greece

  • George Simeakis,
  • Aikaterini Kapama,
  • Rodis D. Paparodis,
  • Pyrros Gkousis and ,
  • Panayiotis Koursaros,
  • Christos Kokkinis,
  • Maria Zozolou and
  • Myrsini Gkeli
  • + 3 authors+ 0 author

Background/Objectives: Structural incomplete response (SIR) (persistence/recurrence) may occur in 2–6% of low-risk differentiated thyroid cancer (DTC)-cases and in 67–75% of high risk. Regarding locoregional disease, surgery is the optima...

(This article belongs to the Section Molecular and Translational Medicine)
  • Article
  • Open Access
10 Citations
5,108 Views
12 Pages

A Multicenter Randomized Phase II Study of Single Agent Efficacy and Optimal Combination Sequence of Everolimus and Pasireotide LAR in Advanced Thyroid Cancer

  • Julie E. Bauman,
  • Zhengjia Chen,
  • Chao Zhang,
  • James P. Ohr and ,
  • Robert L. Ferris,
  • Gerald M. McGorisk,
  • Stephen Brandt,
  • Sumathi Srivatsa,
  • Amy Y. Chen and
  • Taofeek K. Owonikoko
  • + 9 authors+ 4 authors

26 May 2022

Purpose: Aberrant mTOR pathway and somatostatin receptor signaling are implicated in thyroid cancer and offer potential therapeutic targets. We assessed the clinical efficacy of everolimus and Pasireotide long-acting release (LAR) in radioiodine-refr...

(This article belongs to the Special Issue Advances in Thyroid Cancer)
  • Article
  • Open Access
4 Citations
2,886 Views
15 Pages

Using 18F-FDG-PET/CT Metrics to Predict Survival in Ra-Dio-Iodine Refractory Thyroid Cancers

  • Malanie Roy,
  • Agathe Edet-Sanson,
  • Hervé Lefebvre,
  • Pierre Vera and
  • Pierre Decazes

30 September 2022

Radio-iodine refractory (RAI-R) differentiated thyroid cancer (DTC) is a rare disease with a poor prognosis and limited therapeutic resources. Therefore, identifying prognostic factors is essential in order to select patients who could benefit from a...

(This article belongs to the Section Medical Imaging and Theranostics)
  • Review
  • Open Access
67 Citations
8,856 Views
24 Pages

Thyroid Cancers: From Surgery to Current and Future Systemic Therapies through Their Molecular Identities

  • Loredana Lorusso,
  • Virginia Cappagli,
  • Laura Valerio,
  • Carlotta Giani and ,
  • David Viola,
  • Luciana Puleo,
  • Carla Gambale,
  • Elisa Minaldi,
  • Maria Cristina Campopiano and
  • Rossella Elisei
  • + 9 authors+ 4 authors

Differentiated thyroid cancers (DTC) are commonly and successfully treated with total thyroidectomy plus/minus radioiodine therapy (RAI). Medullary thyroid cancer (MTC) is only treated with surgery but only intrathyroidal tumors are cured. The worst...

(This article belongs to the Special Issue Advances in Kinase Drug Discovery)
  • Review
  • Open Access
32 Citations
6,631 Views
28 Pages

Strategies for Radioiodine Treatment: What’s New

  • Clotilde Sparano,
  • Sophie Moog,
  • Julien Hadoux,
  • Corinne Dupuy and ,
  • Abir Al Ghuzlan,
  • Ingrid Breuskin,
  • Joanne Guerlain,
  • Dana Hartl,
  • Eric Baudin and
  • Livia Lamartina
  • + 5 authors+ 0 author

4 August 2022

Radioiodine treatment (RAI) represents the most widespread and effective therapy for differentiated thyroid cancer (DTC). RAI goals encompass ablative (destruction of thyroid remnants, to enhance thyroglobulin predictive value), adjuvant (destruction...

  • Article
  • Open Access
12 Citations
2,944 Views
15 Pages

Adherens Junction Integrity Is a Critical Determinant of Sodium Iodide Symporter Residency at the Plasma Membrane of Thyroid Cells

  • Márcia Faria,
  • José Vareda,
  • Micaella Miranda,
  • Maria João Bugalho and ,
  • Ana Luísa Silva and
  • Paulo Matos
  • + 1 author+ 0 author

31 October 2022

While most cases of differentiated thyroid carcinoma (DTC) are associated with a good prognosis, a significant number progress to advanced disease exhibiting aggressive clinical characteristics and often becoming refractory to radioactive iodine (RAI...

(This article belongs to the Special Issue Thyroid Carcinoma)
  • Review
  • Open Access
1,320 Views
48 Pages

Targeting Sirtuins in Thyroid Cancer: Mechanisms, Drug Development, and Emerging Roles in Tumor Immunity and Ferroptosis

  • Ki Ju Cho,
  • Ji Hyun Seo,
  • Hayeong Kwon,
  • Seung-Jun Lee and ,
  • Young-Sool Hah and
  • Jung Je Park
  • + 1 author+ 0 author

27 June 2026

Thyroid cancer (TC) is the most common endocrine malignancy, with incidence increasing worldwide. Although most differentiated TCs have a favorable prognosis, radioiodine (RAI)-refractory differentiated thyroid cancer (DTC), BRAF inhibitor-resistant...

(This article belongs to the Section Molecular Cancer Biology)
  • Communication
  • Open Access
4 Citations
2,738 Views
11 Pages

Thrombotic Events during Lenvatinib Treatment: A Single Institution Experience

  • Nerina Denaro,
  • Ornella Garrone,
  • Michele Ghidini,
  • Gianluca Tomasello and ,
  • Jens Claus Hahne,
  • Marco Carlo Merlano and
  • Laura Deborah Locati
  • + 2 authors+ 0 author

9 December 2022

Lenvatinib is the standard treatment for radioiodine-refractory differentiated thyroid cancer (RR-DTC). Thromboembolic (TE) side effects are quite rare (1–3% of treated patients) in clinical trials. Nevertheless, patients with predisposing factors ar...

(This article belongs to the Section Oncology)
  • Systematic Review
  • Open Access
6 Citations
2,781 Views
12 Pages

Efficacy and Safety of Pazopanib in the Treatment of Thyroid Cancer: A Systematic Review

  • Alexandra Laura Mederle,
  • Loredana Gabriela Stana,
  • Adrian Cosmin Ilie,
  • Claudia Borza and ,
  • Caius Glad Streian,
  • Daciana Nistor,
  • Teodor Cerbulescu,
  • Biliana Belovan and
  • Ana Lascu
  • + 4 authors+ 0 author

12 December 2024

Pazopanib, a multi-targeted tyrosine kinase inhibitor, has been explored for its efficacy in treating various subtypes of thyroid cancer, including differentiated thyroid carcinoma (DTC), medullary thyroid carcinoma (MTC), and anaplastic thyroid carc...

(This article belongs to the Section Cancer Biology and Oncology)
  • Article
  • Open Access
25 Citations
5,358 Views
15 Pages

Selumetinib Activity in Thyroid Cancer Cells: Modulation of Sodium Iodide Symporter and Associated miRNAs

  • Sabine Wächter,
  • Annette Wunderlich,
  • Brandon H. Greene,
  • Silvia Roth and ,
  • Moritz Elxnat,
  • Sebastian A. Fellinger,
  • Frederik A. Verburg,
  • Markus Luster,
  • Detlef K. Bartsch and
  • Pietro Di Fazio
  • + 5 authors+ 0 author

Background: The MEK (mitogen-activated protein kinase)–inhibitor selumetinib led to increased radioiodine uptake and retention in a subgroup of patients suffering from radioiodine refractory differentiated thyroid cancer (RR-DTC). We aimed to a...

(This article belongs to the Special Issue Cell and Molecular Biology of Thyroid Disorders)
  • Systematic Review
  • Open Access
9 Citations
3,490 Views
13 Pages

The Efficacy and Safety of Anlotinib in the Treatment of Thyroid Cancer: A Systematic Review

  • Calin Muntean,
  • Adelaida Solomon,
  • Remus Calin Cipaian,
  • Razvan Constantin Vonica and ,
  • Anca Butuca,
  • Vasile Gaborean,
  • Ionut Flaviu Faur and
  • Catalin Vladut Ionut Feier
  • + 3 authors+ 0 author

8 January 2025

Background and Objectives: Anlotinib, a novel multi-kinase inhibitor targeting angiogenesis and tumor proliferation pathways, has shown promising efficacy in various cancers. Its role in treating thyroid cancer, particularly radioactive iodine-refrac...

(This article belongs to the Special Issue Thyroid Cancer: Clinical Diagnosis and Treatment)
  • Review
  • Open Access
45 Citations
8,390 Views
29 Pages

Current Advances in Thyroid Cancer Management. Are We Ready for the Epidemic Rise of Diagnoses?

  • Dagmara Rusinek,
  • Ewa Chmielik,
  • Jolanta Krajewska,
  • Michal Jarzab and ,
  • Malgorzata Oczko-Wojciechowska,
  • Agnieszka Czarniecka and
  • Barbara Jarzab
  • + 2 authors+ 0 author

A rising incidence of thyroid cancers (TCs) mainly small tumors, observed during recent years, lead to many controversies regarding treatment strategies. TCs represent a distinct molecular background and clinical outcome. Although in most cases TCs a...

(This article belongs to the Special Issue Cell and Molecular Biology of Thyroid Disorders)
  • Review
  • Open Access
55 Citations
5,645 Views
19 Pages

Activation of the IGF Axis in Thyroid Cancer: Implications for Tumorigenesis and Treatment

  • Livia Manzella,
  • Michele Massimino,
  • Stefania Stella,
  • Elena Tirrò and ,
  • Maria Stella Pennisi,
  • Federica Martorana,
  • Gianmarco Motta,
  • Silvia Rita Vitale,
  • Adriana Puma and
  • Paolo Vigneri
  • + 9 authors+ 4 authors

The Insulin-like growth factor (IGF) axis is one of the best-established drivers of thyroid transformation, as thyroid cancer cells overexpress both IGF ligands and their receptors. Thyroid neoplasms encompass distinct clinical and biological entitie...

(This article belongs to the Special Issue Cell and Molecular Biology of Thyroid Disorders 2.0)
  • Review
  • Open Access
1 Citations
3,416 Views
19 Pages

24 September 2025

Radioiodine-refractory differentiated thyroid cancer (RAIR-DTC) is associated with poor prognosis and limited systemic options. This narrative review focuses on lenvatinib (LEN), a multitarget tyrosine kinase inhibitor that significantly prolongs pro...

  • Article
  • Open Access
581 Views
13 Pages

Real-World Outcomes and Prognostic Factors in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Sorafenib: A Multicenter Study

  • Suheda Atas Ipek,
  • Sendag Yaslikaya,
  • Ismail Oguz Kara,
  • Tolga Koseci and ,
  • Ertugrul Bayram,
  • Esra Asarkaya,
  • Hatice Asoglu,
  • Mehmet Turker,
  • Abdurrahman Aykut and
  • Mahmut Buyuksimsek
  • + 31 authors+ 26 authors

23 June 2026

Background: Sorafenib remains an important treatment option for patients with radioiodine-refractory differentiated thyroid cancer (RAI-R DTC). This study evaluated real-world outcomes and prognostic factors in patients treated with sorafenib. Materi...

(This article belongs to the Section Oncology)
  • Systematic Review
  • Open Access
3 Citations
3,985 Views
19 Pages

Match Point: Nuclear Medicine Imaging for Recurrent Thyroid Cancer in TENIS Syndrome—Systematic Review and Meta-Analysis

  • Fabrizia Gelardi,
  • Alexandra Lazar,
  • Gaia Ninatti,
  • Cristiano Pini and ,
  • Arturo Chiti,
  • Markus Luster,
  • Friederike Eilsberger and
  • Martina Sollini
  • + 3 authors+ 0 author

10 September 2024

Background/Objectives: Disease recurrence and resistance to radioiodine (RAI) therapy are major challenges in the management of differentiated thyroid cancer (DTC). In particular, the TENIS (Thyroglobulin Elevated Negative Iodine Scintigraphy) syndro...

(This article belongs to the Section Nuclear Medicine & Radiology)
  • Article
  • Open Access
2 Citations
2,346 Views
8 Pages

No Correlation between PD-L1 and NIS Expression in Lymph Node Metastatic Papillary Thyroid Carcinoma

  • Lévay Bernadett,
  • Kiss Alexandra,
  • Fröhlich Georgina,
  • Tóth Erika and ,
  • Slezák András,
  • Péter Ilona,
  • Oberna Ferenc and
  • Dohán Orsolya
  • + 3 authors+ 0 author

26 August 2024

Approximately 90% of thyroid cancers are differentiated thyroid cancers (DTCs), originating from follicular epithelial cells. Out of these, 90% are papillary thyroid cancer (PTC), and 10% are follicular thyroid cancer (FTC). The standard care procedu...

(This article belongs to the Section Pathology and Molecular Diagnostics)
  • Review
  • Open Access
9 Citations
8,998 Views
25 Pages

Systemic Therapeutic Options in Radioiodine-Refractory Differentiated Thyroid Cancer: Current Indications and Optimal Timing

  • Tamara Díaz Vico,
  • Brezo Martínez-Amores Martínez,
  • Luka Mihic Góngora,
  • Paula Jiménez-Fonseca and ,
  • Paloma Peinado Martín,
  • Irene Grao Torrente,
  • Alejandro García Muñoz-Nájar and
  • Manuel Durán-Poveda
  • + 3 authors+ 0 author

28 May 2025

Thyroid cancer (TC) remains a prevalent malignancy, with over 820,000 global cases diagnosed in 2022. Differentiated thyroid carcinoma (DTC), primarily papillary and follicular types, accounts for most cases and has a favorable prognosis with total t...

(This article belongs to the Section Cancer Therapy)

of 2